VMVadim P. Mikhin

Vadim P. Mikhin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vadim P. Mikhin has a total of 178 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In-hospital and post-hospital serum high-sensitivity and monomeric C-reactive protein in patients with acute ST segment elevation myocardial infarction and previous COVID-19

    by V.P. Mikhin, A.I. Gindler, I.S. Melnikov, O.S. Saburova, Z.A. Gabbasov, T.A. Nikolenko, M.A. Chernyatina, N.L. Kostina, L.S. Maltseva, S.A. Boytsov

    Objective. To analyze in-hospital and post-hospital (up to 6 months) serum hsCRP and mCRP in patients with acute ST-segment elevation myocardial infarction (STEMI) and previous COVID-19. Material and methods. There were 140 patients with STEMI stratified into 2 groups: 1 — 52 STEMI patients with COVID-19 1.5—6 months before acute coronary syndrome (ACS), 2 — 88 patients with STEMI and no previous COVID-19. PCI with stenting of infarct-related artery was performed on the first day. Serum hsCRP and mCRP were determined in 2 and 10 days, 1 and 6 months after MI. Results. Serum mCRP was higher in the main group at all time points: by 5.09 times after 2 day, 13.50 times after 10 days, 5.70 times after 1 month and 2.41 times after 6 months. In-hospital serum hsCRP was higher in the main group (by 2.05 times after 2 days and 3.36 times after 10 days). Serum hsCRP after 1 and 6 months was equivalent in both groups. Dynamics of serum mCRP and hsCRP was multidirectional after 10 days (mCRP increased, hsCRP did not change in the main group, and both parameters decreased in the control group). After 1 and 6 months, dynamics of these parameters was unidirectional and positive in both groups. Conclusion. Patients with STEMI and previous COVID-19 are characterized by higher concentration of mCRP in the first 6 months and hsCRP in the first month of treatment. This indicates more severe inflammatory reaction in the first 6 months after STEMI.

  • Remodeling of the major arteries of the brain and serum cystatin C levels in patients with non-communicable diseases

    by I.T. Murkamilov, K.A. Aitbaev, V.V. Fomin, Zh.A. Murkamilova, V.P. Mikhin, A.F. Yusupov, T.F. Yusupova, F.A. Yusupov

    Objective. To evaluate serum cystatin C concentrations and the remodeling of major arteries in patients with non-communicable diseases (NCDs). Material and methods. A total of 460 patients diagnosed with NCDs participated in the study, including 229 (49.8%) males and 231 (50.2%) females, with a mean age of 53.4±14.2 years. The subjects were categorized into three groups (1—3) based on serum cystatin C levels. Multiple laboratory, clinical, and instrumental parameters were assessed. Results. In individuals with NCDs, an increase in serum cystatin C from 1 mg/L to 3 mg/L correlated with an elevation in systolic blood pressure from 128±17 mmHg to 145±24 mmHg, and diastolic blood pressure from 84±10 mmHg to 87±12 mmHg. Additionally, total cholesterol levels rose from 4.68±1.00 mmol/L to 5.24±1.91 mmol/L, low-density lipoproteins increased from 3.15±0.88 mmol/L to 3.31±1.56 mmol/L, and triglycerides increased from 1.13 [0.89; 1.61] mmol/L to 1.59 [1.10; 2.45] mmol/L. Potassium levels increased from 4.35±0.61 mmol/L to 4.81±0.96 mmol/L, and creatinine levels rose from 67.3±13.1 μmol/L to 149.4 [102.8; 291.7] μmol/L. C-reactive protein levels rose from 7.8% to 22.8%, and fibrinogen levels increased from 3.0 [2.6; 3.7] g/L to 4.4 [3.3; 5.7] g/L, while urinary protein excretion increased from 423 [0; 100] mg/L to 6722 [0; 1250] mg/L. The estimated glomerular filtration rate decreased from 101.1±15.9 mL/min/1.73 m2 to 44.0 [22.0; 61.0] mL/min/1.73 m2. The diameter of the ascending aorta also increased, from 2.96±0.36 cm to 3.22±0.31 cm, while the prevalence of aortic atherosclerosis rose from 50.0% to 81.3%. The thickness of the intima-media complex (IMC) of the common carotid artery (CCA) increased from 0.87±0.24 mm to 1.04±0.26 mm, and the diameter of the vertebral arteries expanded from 3.47±0.37 mm to 3.62±0.40 mm. A decline in high-density lipoproteins was observed, from 1.16±0.30 mmol/L to 1.09±0.31 mmol/L, and calcium levels decreased from 2.16±0.33 mmol/L to 2.01±0.37 mmol/L. In groups 2 and 3, localized thickening of the CCA IMC of 1.11—1.3 mm was identified in 39 (19.3%) and 22 (18.6%) subjects, respectively. Local thickening of CCA IMC exceeding 1.3 mm was identified in 35 (17.3%) and 21 (17.8%) patients in groups 2 and 3, respectively. Serum cystatin C levels were significantly correlated with the diameter of the ascending aorta (r=0.307; p<0.05), the diameter of the vertebral arteries (r=0.224; p<0.05), and the thickness of the CCA IMC (r=0.324; p<0.05). Conclusion. Measurement of serum cystatin C in patients with non-communicable diseases demonstrates promising diagnostic utility as a laboratory marker of arterial remodeling and reflects the cerebrovascular risk, correlating with the wall thickness of the major arteries of the brain.

  • The possibilities of Mexidol in the complex therapy of arterial hypertension

    by V.P. Mikhin, N.L. Kostina, T.A. Nikolenko, V.V. Savelyeva, M.A. Chernyatina

    A review of the literature is devoted to the effects of the ethylmethylhydroxypyridine succinate (mexidol) in patients with arterial hypertension. The analysis of 44 sources of Russian and foreign literature showed more effective achievement of the target values of blood pressure, prevention of severe complications in hypertensive crises in patients with mexidol therapy. The evidence of the positive effect of cytoprotective therapy on the condition of the left ventricle and vascular wall is considered. The results of large-scale studies demonstrating the effective correction of cognitive dysfunction of the brain using mexidol are presented. The role of the drug in stabilizing of biochemical processes, including lipid peroxidation, glucose and cholesterol metabolism, which determines the pleiotropic effects of mexidol in patients with hypertension, is emphasized.


  • Possibilities of using cytoprotectors in complex therapy of chronic coronary heart disease

    by V.P. Mikhin, N.YU. Borovkova, A.V. Shulyndin

    The chronic form of coronary heart disease (CHD) is one of the most common types of cardiovascular pathology in the Russian Federation. The main causes of myocardial ischemia are a decrease in coronary reserve, as well as a decrease in coronary blood flow due to atherosclerotic stenosis. When cardiac muscle perfusion is impaired, energy deficiency occurs in cardiomyocytes and an ischemic cascade develops, leading to oxidative stress. In conditions of chronic ischemia in ischemic heart disease, therapy should be aimed at maintaining the energy-synthesizing function of mitochondria by activating the least energy- and oxygen-consuming pathways of ATP synthesis, combating oxidative stress and preventing the death of cardiomyocytes. Cytoprotector drugs meet these requirements. One of their most famous representatives is Mexidol — original (biological reference medicine) ethylmethylhydroxypyridine succinate. Anti-ischemic action is achieved by combining of antioxidant, antihypoxic and membrane-stabilizing pharmacological effects. The review presents the experience of using ethylmethylhydroxypyridine succinate in patients with chronic ischemic heart disease from the perspective of studying their effectiveness and safety using clinical, instrumental and laboratory research methods.

  • Open Access

    Heart rate variability in patients with acute ST-segment elevation myocardial infarction after COVID-19

    by V. P. Mikhin, O. A. Osipova, A. I. Gindler, A. S. Brizhaneva, N. V. Zaikina, M. P. Zaikina, T. A. Nikolenko, V. V. Savelyeva, M. A. Chernyatina

    Aim. To compare heart rate variability parameters in patients after a coronavirus disease 2019 (COVID-19) with acute ST elevation myocardial infarction (STEMI) during the inhospital and post-hospital periods. Material and methods. A total of 140 patients with STEMI were divided into 2 groups: I — patients with STEMI who had COVID-19 (n=52) in the period of 1,5-6 months before acute coronary syndrome, II — comparison group (n=88), which included patients with STEMI without prior COVID-19. All patients underwent infarct-related artery stenting within the first 24 hours from the onset. Heart rate variability (HRV) parameters were determined for all patients on days 2-3 and days 9-11 and 6 months after the hospitalization for STEMI. Results. Patients in group I showed more pronounced changes in HRV indicators on days 2-3 of STEMI: RMSSD (root square of successive RR intervals) by 21% (p=0,026), variations (Var) (the difference between the minimum and maximum RR intervals) by 33% (p=0,013), VLF (total very low-frequency HRV) by 7% (p=0,009) were higher, and HF (highfrequency HRV) by 40% (p=0,003), pNN50% (ratio of the number of consecutive RR interval pairs differing by >50 ms to the total number of RR intervals) by 66% (p=0,038) were lower than in the control group, respectively. On days 9-11 of the disease in patients with a history of STEMI and COVID-19, in contrast to the control group, there was a more pronounced increase in the SDNN (standard deviation of RR intervals) by 46% (p=0,005), VLF by 42% (p=0,031), whereas in the control group there were an increase of only 22% (p=0,004) and 11% (p=0,022), respectively. The HF value in the main group increased by 25% (p=0,007), while in the control group it decreased by 19% (p=0,030). Six months after STEMI in the main group, the RMSSD decreased by 19% (p=0,009), Var by 16% (p=0,041), VLF by 30% (p=0,025), LF (low-frequency component HRV) by 11% (p=0,005), while the control group these parameters decreased by 20% (p=0,006), 21% (p=0,001), 9% (p=0,011), and 7% (p=0,016), respectively. Conclusion. In patients with STEMI and prior COVID-19, the initial HRV values differ from similar HRV parameters in patients with STEMI without prior COVID-19. In the hospital and post-hospital periods, the changes of HRV in patients with and without COVID-19 are multidirectional as follows: pronounced sympathetic hyperactivity predominates, and slower recovery of HRV in patients after COVID-19 predominates.


  • Open Access

    Features of cardiac arrhythmias in patients with acute st-segment elevation myocardial infarction who underwent COVID-19

    by Vadim P. Mikhin, Анна Игоревна Гиндлер, Наталья Викторовна Заикина, Маргарита Павловна Заикина, Тамара Александровна Николенко, Valentina V. Savelyeva, Marina A. Chernyatina

    Objective: to conduct a comparative assessment of the parameters of heart rhythm and conduction in patients with Covid-19 with acute ST-segment elevation myocardial infarction (STEMI) in the hospital and post-hospital treatment periods. Materials and methods. The study included 140 patients with STEMI, stratified into 2 groups: I - the main (52 people) patients with STEMI who had COVID-19 for 1.5-6 months before the development of acute coronary syndrome (ACS), II - the comparison group (88 people) with STEMI without COVID-19 in the anamnesis. All patients underwent percutaneous coronary intervention with stenting of a single infarct-related artery in the first 24 hours. Daily ECG monitoring was performed with an assessment of traditional heart rate and conduction parameters for 2-3 days, 9-11 days and after 6 months from the moment of the accident. Results. In the main group, in contrast to the control group, a shortening of the QT interval (7.7% vs. 0.0%), ventricular extrasystole (VES) of Lown grade IV A (25.0% vs. 7.9%) was more often recorded on 2-3 days. Supraventricular extrasystole (SVE; 92.0% vs. 65.4%), sinus arrhythmia (37.5% vs. 0.0%), supraventricular tachycardia (SVT; 7.9% vs. 0.0%) were more often recorded in group II on 2-3 days. During the hospital follow-up period, the retention of shortened QT (7.7% vs. 0.0%), predominance SVE (90.4% vs. 76.1%), sinus arrhythmia (48.1% vs. 29.5%), migration of the rhythm driver along the atria (15.3% vs. 0.0%), VES Lown grade IV A (9.6 % vs. 0.0%). In the control group, AV blockade of 1 deg. (15.9% vs. 3.8%), AV blockade of 2 deg. (4.5% vs. 0.0%), CA blockade (3.4% vs. 0.0%), QT prolongation (12.5% vs. 0.0%) were more often determined. By 6 months after STEMI, patients in the main group were more likely to have SVT (9.6% vs. 0.0%) and VES Lown grade IV A (7.6% vs. 0.0%). In the control group, AV blockade of 1 deg. (9.0% vs. 0.0%), CA blockade (3.4% vs. 0.0%) were registered. Conclusion. Patients with STEMI who had a history of COVID-19 and without COVID-19 had a multidirectional dynamics of heart rate and conduction parameters during the hospital and post-hospital follow-up periods. In patients who underwent COVID-19, there was a predominance of ventricular arrhythmias of high Lown gradations on 2-3 days of STEMI, an increase in supraventricular arrhythmias on days 9-11, an increase in supraventricular and ventricular arrhythmias of high Lown gradations and the absence of CA and AB disorders after 6 months. In the control group, there was a predominance of supraventricular and ventricular arrhythmias of low gradations according to Lown, a predominance of CA and AB conduction disorders on days 9-11 and 6 months after STEMI.


  • Open Access

    Features of intracardiac hemodynamics in patients with acute myocardial infarction with st segment elevation who underwent COVID-19

    by Vadim P. Mikhin, Анна Игоревна Гиндлер, Наталья Викторовна Заикина, Маргарита Павловна Заикина, Тамара Александровна Николенко, Valentina V. Savelyeva, Marina A. Chernyatina, Антон Михайлович Александров

    Objective: to evaluate the features of central and intracardiac hemodynamics in patients with ST-segment elevation myocardial infarction (STEMI), who underwent COVID-19 during inpatient stay and 6 months after the development of STEMI. Materials and methods. 140 patients with STEMI were included in the study. The patients were randomized into 2 groups: I - main group - patients with STEMI who suffered COVID-19 (52 people) in the period from 1.5-6 months before the development of acute coronary syndrome (ACS), II - comparison group (88 people) which included patients with STEMI who did not have COVID-19 in the anamnesis. All patients underwent PCI with stenting of the infarct-related artery in the first 24 hours from the onset of ACS. The parameters of central and intracardiac hemodynamics in all patients were determined for 2-3 days (1st control point), 9-11 days (2nd control point), after 6 months (3rd control point) from the moment of hospitalization for STEMI. Results. In the patients of the main group of the study, more pronounced changes in the systolic-diastolic LV function were recorded on the 2-3 day of STEMI: LV EF by 8.5%, Sm by 7.2% and E' by 24.5% (p<0.05) were lower than in the control group, respectively, E/E' by 11.5% and WMSI by 21.8% (p<0.05) were higher than in the comparison group. On the 9th-11th day of the disease in patients with STEMI who underwent COVID-19, a slowdown in the recovery of the studied parameters was revealed: the LV EF value was lower than in the control group by 11%, Sm by 12% and E' by 20% (p<0.05), respectively, and the value of E/E' by 27% and WMSI by 25% (p<0.05) were higher than in the comparison group. 6 months after STEMI, there were no significant differences in Sm, E', E/E' values in the main and control groups, however, a lower LVEF and WMSI value was noted in comparison with the control group (p<0.05). Conclusion. Unidirectional positive dynamics of systolic-diastolic function parameters in hospital and post-hospital follow-up periods was observed in patients with STEMI, both those who had COVID-19 and without COVID-19 in the anamnesis. However, in patients who underwent COVID-19, there were more pronounced violations of LV systolic-diastolic function on 2-3 days and less pronounced, delayed positive dynamics of these parameters during the hospital and post-hospital treatment periods.


  • Open Access

    Content of matrix metalloproteinases in the blood of hypertensive patients with a high cardiovascular risk receiving statin therapy

    by V. P. Mikhin, O. A. Osipova, V. V. Vorotyntseva, D. N. Perutsky, N. I. Golovina

    Aim. To compare the effect of atorvastatin and rosuvastatin as part of complex therapy in patients with hypertension (HTN) with a high cardiovascular risk on the level of matrix metalloproteinases -1, -9 (MMP-1, MMP-9) and tissue inhibitors of metalloproteinases -1, -4 (TIMP-1, TIMP-4).Material and methods. The study included 140 hypertensive patients who received atorvastatin (Liprimar) 20 mg/day in addition to antihypertensive therapy for a year, which was later replaced by rosuvastatin (Rosucard) in the following doses: 10 mg/day (n=96), 20 mg/day (n=24), 40 mg/day (n=26). Patients underwent standard clinical and paraclinical investigations. In the blood serum of patients, the levels of MMP-1, MMP-9 and TIMP-1, TIMP-4 were determined.Results. Patients who used rosuvastatin at a dose of 40 mg/day had a more pronounced decrease in MMP-1 than those treated with rosuvastatin at a dose of 10 and 20 mg/day (p0,05). The content of TIMP-1 and TIMP-4 increased when taking rosuvastatin, while a more pronounced dose-dependent increase in TIMP-1 was observed with rosuvastatin 20 mg/day and 40 mg/day. In addition, the largest increase in TIMP-4 was observed when using rosuvastatin at a dose of 40 mg/day. Atorvastatin had no significant effect on MMP-1 and MMP-9, as well as TIMP-1 and TIMP-4.Conclusion. Long-term rosuvastatin therapy (10 mg/day, 20 mg/day, 40 mg/day) as part of the complex therapy of cardiovascular patients affects the metabolism of vascular wall elastin and collagen, reducing the level of MMP-1, MMP-9 and increasing the content of TIMP-1, TIMP-4 in the blood.


  • Open Access

    Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome

    by O. A. Osipova, V. P. Mikhin, A. I. Golovin, O. N. Belousova, D. N. Perutsky, P. K. Alferov, S. L. Konstantinov

    Aim.To conduct a comparative analysis of the effect of long-term pharmacotherapy (12 months) using a β-blocker (nebivolol) and its combination with eplerenone in patients after ST-segment elevation acute coronary syndrome (STE-ACS) with heart failure with mildly reduced ejection fraction (EF) (HFmrEF) on the structural and functional cardiac parameters.Material and methods. We examined 130 patients with STE-ACS and HFmrEF after successful myocardial revascularization by percutaneous coronary intervention. The mean age of patients was 53,6 [46;57] years. Ten patients withdrew from the study due to personal reasons. Subsequently, patients were randomly divided into 2 treatment groups as follows: 60 patients received nebivolol; 60 patients received nebivolol and eplerenone. Patients were examined at two stages: 1st day of the disease before PCI and 12 months later. All patients underwent a clinical examination, echocardiography, followed by assessment of left ventricular (LV) EF, LV end-diastolic volume index (EDVI), LV endsystolic volume index (ESVI), LV myocardial index (LVMI), LV wall motion score index (WMSI), the ratio of peak early diastolic flow over peak late diastolic flow (E/A), the ratio of early diastolic transmitral flow velocity to the mitral annular velocity (E/e´).Results.Twelve-month pharmacotherapy with nebivolol in patients after STE-ACS showed an increase in LVEF by 7,2% (pConclusion.The advantages of long-term combination pharmacotherapy of nebivolol and eplerenone in HFmrEF patients after STE-ACS on both structural and functional cardiac parameters were established.

  • Open Access

    Patients with a Combination of Atrial Fibrillation and Chronic Heart Failure in Clinical Practice: Comorbidities, Drug Treatment and Outcomes

    by M. M. Loukianov, S. Yu. Martsevich, Yu. V. Mareev, S. S. Yakushin, E. Yu. Andreenko, A. N. Vorobiev, K. G. Pereverzeva, A. V. Zagrebelny, E. Yu. Okshina, Vl. Vl. Yakusevich, et al.

    Aim. To assess in clinical practice the structure of multimorbidity, cardiovascular pharmacotherapy and outcomes in patients with a combination of atrial fibrillation (AF) and chronic heart failure (CHF) based on prospective registries of patients with cardiovascular diseases (CVD).Materials and Methods. The data of 3795 patients with atrial fibrillation (AF) were analyzed within the registries RECVASA (Ryazan), RECVASA FP (Moscow, Kursk, Tula, Yaroslavl), REGION-PO and REGION-LD (Ryazan), REGION-Moscow, REGATA (Ryazan). The comparison groups consisted of 3016 (79.5%) patients with AF in combination with CHF and 779 (29.5%) patients with AF without CHF. The duration of prospective observation is from 2 to 6 years.Results. Patients with a combination of AF and CHF (n=3016, age was 72.0±10.3 years; 41.8% of men) compared with patients with AF without CHF (n=779, age was 70.3±12.0 years; 43.5% of men) had a higher risk of thromboembolic complications (CHA2DS2-VASc – 4.68±1.59 and 3.10±1.50; pConclusion. Patients with a combination of AF and CHF, compared with the group of patients with AF without CHF, were older, had a higher risk of thromboembolic and hemorrhagic complications, they were more often diagnosed with other concomitant cardiovascular and chronic noncardiac diseases, decreased left ventricular ejection fraction, tachysystole, failure to achieve the target blood pressure level in the presence of arterial hypertension. The frequency of prescribing proper cardiovascular pharmacotherapy was higher, albeit insufficient, in the presence of CHF, while the frequency of prescribing anticoagulants was less. The incidence of mortality from all causes, the development of non-fatal myocardial infarction and cerebral stroke, as well as the incidence of hospitalizations for CVDs were higher in AF associated with CHF.